Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jinxin Fertility Group Ltd. ( (HK:1951) ) has shared an announcement.
Jinxin Fertility Group has launched trial operations at the new campus of Shenzhen Zhongshan Obstetrics and Gynecology Hospital, a centrally located facility four times larger than its original site, enabling expansion into VIP, specialty and international medical services. The Shenzhen operations recorded an 18% rise in oocyte pick-up cycles in the first two months of 2026 versus a year earlier, underscoring robust volume growth from the enlarged capacity.
In the U.S., HRC Fertility clinics under Jinxin’s management reported a 38% increase in oocyte pick-up cycles over the same period, driven by higher local demand after California’s IVF insurance mandate for large employers took effect in January 2026. The company said it will continue to optimize operations, upgrade core reproductive technologies and enhance patient care to support sustainable long-term growth and strengthen its position in the global fertility services market.
The most recent analyst rating on (HK:1951) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
More about Jinxin Fertility Group Ltd.
Jinxin Fertility Group Limited operates in the reproductive medicine and fertility services industry, providing assisted reproductive treatments and obstetrics and gynecology care through hospitals and clinics in China and the United States. The group focuses on advanced reproductive technologies, VIP and specialized medical services, and international patient offerings, positioning itself to capture growing demand for fertility solutions in key urban and overseas markets.
Average Trading Volume: 19,273,136
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.5B
Learn more about 1951 stock on TipRanks’ Stock Analysis page.